Clinical Trial Update: Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated whether adding GI-5005 to pegylated interferon plus ribavirin improves outcomes versus standard of care in genotype 1 chronic hepatiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GI-5005
• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: GlobeImmune | Conditions: Genotype 1 Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2014-06-03